CYCN Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc. (CYCN) is expected to report earnings on November 3, 2026, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of +8.6% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. The company's product pipeline consists of Olinciguat, Praliciguat and IW-6463 which are in clinical stage. Cyclerion Therapeutics Inc. is based in Cambridge, United States.
Sector
Healthcare
Industry
Biotechnology